135 related articles for article (PubMed ID: 38360802)
21. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
Mayor S
BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
[No Abstract] [Full Text] [Related]
22. Lowering LDL cholesterol is good, but how and in whom?
Stone NJ; Lloyd-Jones DM
N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
[No Abstract] [Full Text] [Related]
23. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
[TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease.
Stein EA
Mayo Clin Proc; 2009 Apr; 84(4):307-9. PubMed ID: 19339646
[No Abstract] [Full Text] [Related]
25. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
26. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].
Håkansson J
Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497
[No Abstract] [Full Text] [Related]
27. Low-density lipoprotein cholesterol: how low can we go?
Sherbet DP; Garg P; Brilakis ES; Banerjee S
Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
[TBL] [Abstract][Full Text] [Related]
28. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
Mooradian AD
J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):598; author reply 602. PubMed ID: 16094774
[No Abstract] [Full Text] [Related]
29. [Considerable LDL lowering is advantageous].
MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
[No Abstract] [Full Text] [Related]
30. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?
Aronow WS
J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):591-2. PubMed ID: 15972605
[No Abstract] [Full Text] [Related]
31. LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y.
Elgendy IY; Elshazly MB
Ann Intern Med; 2021 Apr; 174(4):JC38. PubMed ID: 33819068
[TBL] [Abstract][Full Text] [Related]
32. Should every patient with diabetes receive a statin?
Dembowski E; Davidson MH
Pol Arch Med Wewn; 2008; 118(7-8):398-401. PubMed ID: 18714733
[No Abstract] [Full Text] [Related]
33. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Cholesterol and the aged: ...and the beat goes on.
Wilson MM
J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):600-2; author reply 602. PubMed ID: 15972610
[No Abstract] [Full Text] [Related]
34. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Covington AM; DePalma SM; Minissian MB; Orringer CE; Smith SC; Waring AA; Wilkins JT
J Am Coll Cardiol; 2022 Oct; 80(14):1366-1418. PubMed ID: 36031461
[No Abstract] [Full Text] [Related]
35. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
[TBL] [Abstract][Full Text] [Related]
36. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
[TBL] [Abstract][Full Text] [Related]
37. Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.
Kelsey MD; Newby LK
Ann Intern Med; 2022 Aug; 175(8):JC86. PubMed ID: 35914252
[TBL] [Abstract][Full Text] [Related]
38. Do PCSK9 inhibitors reduce cardiovascular events?
Kolber MR; Nickonchuk T; Turgeon R
Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
[No Abstract] [Full Text] [Related]
39. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
40. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
